Tryptophan is metabolized along the kynurenine and serotonin pathways, resulting in formation of kynurenine metabolites, neuroactive serotonin and melatonin. Each pathway is critical for maintaining healthy homeostasis. However, the two pathways are extremely unequal in their ability to degrade tryptophan, and little is known about the mechanisms maintaining the balance between them. Here, we demonstrated that in PC12 cells, a change of expression of key genes of one pathway resulted in a change of expression of key genes of the other. Melatonin, the end product of the serotonin pathway, played an important role in tryptophan metabolism by affecting both key enzymes of the two pathways. Melatonin treatment induced the expression of indole-2,3-dioxygenase 1 (IDO1) and enhanced the activity of the IDO1 promoter while decreasing the expression of arylalkylamine N-acetyl transferase. Melatonin treatment up-regulated the expression of forkhead box protein O1 (FoxO1) and enhanced the binding of FoxO1 to the IDO1 promoter. FoxO1 was shown to be a new regulator for IDO1 expression. Melatonin treatment decreased the phosphorylation of FoxO1 by extracellular signal-regulated kinases 1 and 2 and protein kinase B (Akt) and increased the phosphorylation of binding protein 14-3-3 by c-Jun N-terminal kinase (JNK), and thus the complex of FoxO1-14-3-3 in the cytoplasm was disassembled and FoxO1 was relocated to the nucleus to induce IDO1 expression. The JNK signaling pathway played an important role in melatonin-induced IDO1 up-regulation. In conclusion, this study suggests a link between melatonin, JNK, FoxO1 and IDO1 that acts as a potential balance regulator of tryptophan metabolism, and offers a new approach to treat diseases related to dysregulation of tryptophan metabolism.
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Introduction
Tryptophan (Trp) is the least abundant of all essential amino acids in mammals [1] . In addition to functional protein synthesis, tryptophan is metabolized along the kynurenine (Kyn) and serotonin (5-HT) pathways [2] , producing an array of kynurenine metabolites such as kynurenic acid, 3-hydroxykynurenine, quinolinic acid and nicotinamide adenine dinucleotide [3, 4] , as well as a variety of neuroactive substances including the wellknown neurotransmitters serotonin and melatonin [5] . Indoleamine 2,3-dioxygenase (IDO) 1 (EC 1.13.11.52) and arylalkylamine N-acetyltransaminase (AANAT, EC 2.3.1.87) are the most important rate-limiting enzymes for the kynurenine and serotonin pathways, respectively [6, 7] . The two pathways of tryptophan metabolism have been implicated in the regulation of a number of immune and nerve diseases [6, 8] .
However, little is known about the interplay between the two tryptophan metabolic pathways. The importance of cross-talk between the serotonin and kynurenine pathways of tryptophan metabolism is further stressed by the hypothesis that depression is triggered by a shift of tryptophan metabolism from the formation of serotonin and melatonin toward the production of kynurenine and its metabolites [9] . It was observed that IDO1 activity and depressive rating were increased in chronic hepatitis C patients receiving interferon-c (IFN-c) treatment [10, 11] . It was also found that melatonin, an end metabolite of the serotonin pathway, was responsible for modulating IDO1 mRNA expression and thereby kynurenine production in fibroblasts and melanocytes [12] , and regulating the expression of the forkhead transcription factors [13, 14] . However, despite considerable advances in our understanding of tryptophan metabolism, many critical questions remain unresolved, mainly revolving around (a) how key tryptophan metabolites influence and regulate the tryptophan metabolic pathways, and (b) the mechanism responsible for the intergration and interdependence of the two pathways.
Melatonin (N-acetyl-5-methoxytryptamine) is synthesized enzymatically from L-tryptophan by sequential actions of four enzymes: tryptophan hydroxylase (TPH, EC 1.14.16.4), aromatic amino acid decarboxylase (AADC, EC 4.1.1.28), arylalkylamine N-acetyltransferase (AANAT, EC 2.3.1.87) and hydroxyindole-O-methyltransferase (HIOMT, EC 2.1.1.4) [15] . As an endogenous hormone, melatonin is mainly produced by the pineal gland, modulating a great variety of physiological processes, including the regulation of antigonadotropic [16, 17] and neuroprotective effects [17, 18] , behavioral functions [19] , circadian rhythms [20] , anti-inflammatory [21] and antioxidant activity [20, 22, 23] , and the stimulation of immune function [8] . A recent study suggested that melatonin could be used as a novel therapeutic to treat some cancers [24] .
Indole-2,3-dioxygenase 1 is an intracellular heme enzyme and the initial rate-limiting enzyme of the kynurenine pathway [6] . The overexpression of IDO1 has been found in the dendritic cells, tumor-draining lymph nodes and in a variety of tumor cells [25, 26] . It has also been known that IDO1 plays crucial roles in various infectious diseases, fetal rejection, organ transplantation, neuropathology diseases, autoimmune disorders and cancers by reducing the availability of tryptophan [27] [28] [29] [30] and producing its downstream metabolites (such as Kyn and quinolinic acid) as well as metabolite-mediated signalings [6, 29] . The induction of IDO1 expression is regulated mainly by both INFc-dependent and -independent mechanisms [6] . The binding of INF-c to specific receptors leads to the activation of janus kinase (JAK) and the phosphorylation of downstream substrates such as signal transducer and activator of transcription (STAT) [31, 32] , thus resulting in the activation of transcription factors of interferon regulatory factor 1 (IRF-1) [33] . IRF-1 is able to bind ISRE sequences of IDO1 promoter to induce IDO1 transcription [6] . The expression of IDO1 also can be induced through the activation of the noncanonical nuclear factor kappa B (NF-jB) [34] [35] [36] , cjun N-terminal kinase (JNK) [37, 38] and p38 [39] pathways by bacterial lipopolysaccharide and other inducers. It has been reported that the forkhead transcription factor FoxO3 can induce the expression of immune-suppressive genes including IDO1, TGF-b and ARG1 in tumor associated dendritic cells (TADCs); and when the FoxO3 gene was silenced by siRNA, the tolerogenicity of TADCs was weakened [40] [41] [42] . It could be supposed that forkhead transcription factors such as FoxO1/FKHR, FoxO3a/ FKHRL1 and FoxO4/AFX might be potential targets that programme inflammation vs tolerogenicity [40] [41] [42] . However, the roles of other forkhead transcription factors, except for FoxO3, in the regulation of IDO1 expression have remained relatively unexplored. Combining the effects of melatonin on the expression of both IDO1 and forkhead transcription factor [13, 14] , it might be deduced that forkhead transcription factors could mediate the effect of melatonin on IDO1 expression.
In the present study, we investigated the correlation between the two tryptophan metabolic pathways in rat adrenal pheochromocytoma (PC12) cells, in which the existence of the two pathways was validated. We studied the effects of knock down or overexpression of some key genes on the expression of other key genes. We examined the effects of melatonin on tryptophan metabolism as well as the expression and activity of IDO1. We clarified the involvement of FoxO1 in the melatonin-induced IDO1 up-regulation and the mechanism behind it including the role of the JNK, JAK2-STAT1 and NF-jB signaling pathways. In conclusion, this study reveals a link between the two pathways of tryptophan metabolism and provides new insights into the mechanisms regulating tryptophan metabolism.
Results

Validation of tryptophan metabolism in PC12 cells
Although tryptophan metabolism is widely distributed in mammalian cells, not every type of cell possesses both kynurenine and serotonin pathways. Previous studies show that IDO1, IDO2 and tryptophan 2,3-dioxygenase (TDO) are able to catalyze the degradation of the essential amino acid tryptophan to nicotinamide adenine dinucleotide along the kynurenine pathway; however, TDO is mainly expressed in liver and IDO2 has very low Trp degradation activity [1, [43] [44] [45] . Therefore, IDO1 is the most important rate-limiting enzyme for the kynurenine pathway. To determine whether these two pathways co-existed in PC12 cells, we first evaluated the mRNA and protein expression profiles of key genes involved in these two tryptophan metabolic pathways. As shown in Fig. 1B , RT-PCR products of the total RNA samples yielded bands corresponding to IDO1 and IDO2 in the kynurenine pathway, and TPH1, TPH2, AANAT and HIOMT in the serotonin pathway. Immunoblot results (Fig. 1C) confirmed the expression of the key enzymes IDO1 and AANAT. The catalytic activities of both kynurenine and serotonin pathways were evaluated by measuring the levels of kynurenine in the kynurenine pathway and melatonin in the serotonin pathway by HPLC (Fig. 1D) . Thus, the presence of both kynurenine and serotonin pathways of tryptophan metabolism in PC12 cells was validated.
Shifts of kynurenine and serotonin pathways to keep the balance of tryptophan metabolism in PC12 cells
Using gene knockdown and overexpression methods, we explored the correlation between the kynurenine and serotonin pathways that coexist in PC12 cells. Our initial focus was on the effects of IDO1 gene silencing.
To facilitate this study, PC12 cells were transfected with the piGENE plasmids containing interference sequences respectively targeting three different positions of IDO1 gene, or a scramble sequence as a mock control. After puromycin selection, three stable IDO1 knockdown cell lines, rIDO1-shRNA1, rIDO1-shRNA2 and rIDO1-shRNA3, were established. As shown in Fig. 2A ,B, the mRNA expression levels of IDO1 were down-regulated by 62%, 74% and 53%, respectively, while the expression levels of AANAT were all significantly up-regulated in the rIDO1-shRNA1, rIDO1-shRNA2 and rIDO1-shRNA3 cell lines. Next, the total protein lysates were isolated from the cells and an equal amount of the proteins (20 lg) was applied to western blot analysis. As shown in Fig. 2C , the protein levels of IDO1 were significantly down-regulated, while AANAT were significantly upregulated. These results demonstrated that IDO1 knockdown triggered the down-regulated expression of the IDO1 gene and the up-regulated expression of the AANAT gene. In other words, a shift of key gene expression in both kynurenine and serotonin pathways occurred in order to keep the balance of tryptophan metabolism. Secondly, we focused on the effects of serotonin pathway up-regulation. To facilitate this study, PC12 cells were transfected with plasmids containing TPH1, AANAT and TPH1-AANAT, respectively. There was a trend towards higher expression of AANAT in cells with co-overexpression of THP1-AANAT in comparison with the single overexpression of THP1 or AANAT (Fig. 2D) . To address whether the overexpressed AANAT also affected the kynurenine pathway, we cross-examined the mRNA expression levels of IDO1 in the same cells. As shown in Fig. 2E , the mRNA expression levels of IDO1 were substantially down-regulated when THP1, AANAT or both THP1 and AANAT were overexpressed. It was reported that IDO1 expression was induced by IFN-c through the JAK-STAT signaling pathway [46, 47] . Thus, we treated three stable IDO1 knockdown cell lines with IFN-c at different concentrations (100 or 500 U). We found that the protein expression levels of IDO1 were increased, as expected, upon IFN-c treatment, while AANAT expression levels were decreased accordingly (Fig. 2G ). In addition, we found that after the IFN-c treatment or the transfection of the IDO1-expressing plasmid pVitro2-IDO1, the overexpression of IDO1 led to the down-regulation of AANAT (Fig. 2H,I ). Overall, these results demonstrated that changes of the expression of a key gene in one pathway could trigger changes of expression of key genes in the other pathway of tryptophan metabolism; thus, shifts in the two pathways appeared to be necessary to keep the balance of tryptophan metabolism in the cells.
Effects of melatonin on tryptophan metabolism
A previous study showed that IDO1 mRNA expression was up-regulated in response to melatonin treatment in fibroblasts and melanocytes [12] . To investigate whether there was a similar effect of melatonin on tryptophan metabolism in PC12 cells, we treated the cells with melatonin at different concentrations (from 0 to 2 mM) and for different time lengths (1 mM, from 0 to 72 h). Next, we examined the mRNA and protein expression levels of the key genes IDO1 and AANAT. As shown in Fig. 3A , upon the treatments of melatonin, the mRNA expression levels of IDO1 were enhanced, reaching a peak at 6 h. Figure 3B showed that the effects of melatonin treatments on IDO1 expression were dose-dependent. Figure 3A , B also revealed that the down-regulated expression of AANAT upon melatonin treatment was contrary to that of IDO1, and this contrary observation was confirmed by western blot analysis (Fig. 3C,D) . Thus, these results demonstrated the shifts of the key gene expression in the both pathways upon melatonin treatment. To further investigate the role of melatonin in tryptophan metabolism, we assessed the activity of IDO1 promoter using luciferase reporter assay. As shown in Fig. 3E , compared with the untreated cells, stronger activity of IDO1 promoter was detected after melatonin treatment for 6 h. Taken together, these data support the notion that melatonin had significant effects on tryptophan metabolism.
Effect of melatonin on PC12 cell proliferation
It was previously reported that the activation of IDO1 could inhibit the proliferation and differentiation of mesenchymal stem cells [48] , and melatonin was thought to inhibit tumor growth and block tumor angiogenesis in mice [49] [50] [51] . To assess the effect of melatonin on PC12 cell proliferation, we treated the cells with melatonin at different concentrations (from 0 to 2 mM) for 72 h and performed 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. As shown in Fig. 4 , upon melatonin treatments, cell viabilities were inhibited and responded in a dose-dependent manner. Thus, these results suggest that melatonin affected the proliferation of PC12 cells through the up-regulation of IDO1.
Effects of melatonin on IDO1 activity and expression
It was previously reported that melatonin treatment regulated IDO1 expression, but in response to melatonin treatment the heterogeneity of IDO1 mRNA expression was notable [12] . Therefore, it was necessary to investigate whether the activity and expression of IDO1 could also be modulated by melatonin in PC12 cells. First, we performed in vitro IDO1 inhibition assays using recombinant rat IDO1 (not shown) and melatonin at different concentrations as well as a classic IDO1 inhibitor, 1-methyl-L-tryptophan (1-L-MT), as a positive control. As shown in Fig. 5A , we found that melatonin was hardly able to inhibit the activity of IDO1 in comparison with 1-L-MT. Next, we measured the Kyn/Trp ratios in the cells treated with melatonin, 1-L-MT and IFN-c, respectively (Fig. 5B ). After 1 mM melatonin treatment, the Kyn/ Trp ratio was increased fourfold in comparison with that of the cells treated with 500 lM 1-L-MT (Fig. 5B) . Western blot analysis of the whole protein lysates isolated from cells that were transfected with pVitro2 and pVitro2-IDO1 plasmids. The lower or left part of (C-I) shows the density metric analysis of corresponding bands in the upper or right part. The differences were deemed statistically significant at P < 0.05 by Student's t-test; *P < 0.05, **P < 0.01 (A-I).
Similar results were obtained in the cellular IDO1 inhibition assays (Fig. 5C ). Taken together, these results ( Fig. 5A-C) indicated that melatonin was not an inhibitor of IDO1 at the enzymatic level but increased the formation of kynurenine in PC12 cells. In addition, we found a tendency for IDO1 expression in PC12 cells to be repressed by 800 lM 1-L/D-MT treatment for 36 h and this repression level was reversed through additional melatonin treatment (2 mM for 12 h) (Fig. 5D) . The different effects of 1-L/D-MT on IDO1 expression had been previously reported [52, 53] . One study found that 1-D-MT up-regulated the expression of IDO1 in human SKOV-3 cells [52, 53] , and another found that 1-D-MT suppressed the expression of IDO1 in mouse dendritic cells [52, 53] . Therefore, it appeared that the discrepancies of 1-D-MT effects on IDO1 expression might be due to different species and cell types. Similarly, in the three stable IDO1 knockdown PC12 cell lines, the reduced expression levels of IDO1 by 1-L/D-MT treatments were recovered after melatonin treatment, whereas the protein expression levels of AANAT were correspondingly down-regulated (Fig. 5E ). Taken together, these results further confirmed that melatonin could induce IDO1 expression and did not inhibit IDO1 activity.
Involvement of FoxO1 in the melatonin-induced IDO1 up-regulation
As an evolutionarily conserved family, FoxO transcription factors are involved in diverse cellular and physiological processes. A previous study found that The whole protein lysates of the treated cells were immunoblotted with antibodies against IDO1, AANAT and GAPDH. (E) The enhanced activity of IDO1 promoter in melatonin-treated PC12 cells was analyzed by luciferase assays. The full length of an IDO1 promoter was subcloned into a pGL3-basic vector yielding a pGL3-IDO1 promoter vector with a luciferase reporter. PC12 cells were transfected with pGL3-rIDO1 promoter and pRL-TK vectors and luciferase activities, reflecting the activity of IDO1 promoter, were analyzed using a luciferase assay kit (Promega). The differences were deemed statistically significant at P < 0.05 by Student's t test; *P < 0.05, **P < 0.01.
transcription factor FoxO1 was involved in mediating immune tolerance [40] . To address the relationship between FoxO1 and IDO1 in this study, we initially examined the expression of FoxO1 in stable IDO1 knockdown cells. We found that the expression of FoxO1 was significantly down-regulated in these stable IDO1 knockdown cells (Fig. 6A) . Next, we evaluated the effects of melatonin on the RNA expression profiles of FoxO1 along with other well-known IDO1 regulators including positive regulators such as IRF-1 [54] , NF-jB [55] and STAT1 [46] and negative regulators such as suppressor of cytokine signaling 1 (SOCS1) [56] , Myc-interacting protein Bin1 [57] and TYRO protein tyrosine kinase-binding protein (Tyrobp) [56] [57] [58] by quantitative real-time PCR (qPCR). As shown in Fig. 6B , melatonin induced the mRNA expression of FoxO1, the positive regulators IRF-1, NF-jB and STAT1, but repressed the mRNA expression of the negative regulators SOCS1, Bin1 and Tyrobp. Taken together (Fig. 6A,B) , our results indicated that FoxO1 might be a novel regulator correlated to IDO1 expression. To further explore the role of FoxO1 in the regulation of IDO1 expression, the PC12 cells were transfected by siRNA targeting FoxO1 and FoxO1-expressing plasmid pEGFP-FoxO1, and western blot analysis confirmed that transcription factor FoxO1 was able to modulate IDO1 expression (Fig. 6C) . It was reported that FoxO1 could bind two recognition sequences:
of the insulin responsive element (IRE) and 5 0 -GTAAA(T/C)AA-3 0 of the Daf-16 family binding element [59, 60] . Therefore, we analyzed the sequence of the IDO1 promoter, and identified the sequence of CAAAACAA (IRE) in the IDO1 promoter. Next, we performed chromatin immunoprecipitation (ChIP) assays to confirm the association of FoxO1 with the IRE located in the IDO1 promoter region. The PC12 cells were pretreated with 1 mM melatonin for 2 h and the DNA amplified by a pair of primers flanking the FoxO1 binding site of IRE (CAAAACAA) in the proximal IDO1 promoter region was analyzed by qPCR. As shown in Fig. 6D , the end products increased 7.01-fold after melatonin treatment, indicating that melatonin enhanced the binding of FoxO1 to the IDO1 promoter. To further demonstrate the direct binding of FoxO1 to the IDO1 promoter, an electrophoresis mobility shift assay (EMSA) was performed to clarify the binding of nuclear FoxO1 and IDO1 promoter DNA. After the cells were pretreated with 1 mM melatonin for 2 h, the nuclear extracts were isolated and incubated with biotin-labeled IDO1 promoter DNA as a labeled probe. As shown in Fig. 6E , the resulting complex of FoxO1 protein-IDO1 DNA was visualized by chemiluminescence detection in lane 4, and with the supplement of unlabeled probe (unlabeled IDO1 promoter DNA) as a competitor, the formation of complexes (lanes 2 and 3) was inhibited. Taken together, these results indicated that FoxO1 mediated the expression of IDO1 and was involved in the melatonin-induced IDO1 up-regulation.
The role of JNK signaling pathway in FoxO1-mediated IDO1 expression It was previously reported that melatonin increased the phosphorylation of FoxO1 [61] . We further investigated whether and how the melatonin treatment affected FoxO1 phosphorylation in PC12 cells, and what signal pathway was involved. To facilitate this study, PC12 cells were pretreated for 1 h with various phosphorylation inhibitors, including SP600125 (JNK inhibitor), LY294002 [phosphoinositide 3-kinase (PI3K) inhibitor], PD98059 [ERK1/2, extracellular signal-regulated kinases 1 and 2 (ERK1/2) inhibitor], and the cells were subsequently treated with 1 mM melatonin for 1 h. As shown in Fig. 7A , the expression levels of IDO1 and pFoxO1 were increased in melatonin-treated cells, and the increase was blocked by JNK, ERK1/2 and protein kinase B (Akt) inhibitors, respectively. Upon 1 mM melatonin treatment for different lengths of time, the phosphorylation of JNK, Akt and ERK1/2 increased in a time-dependent manner, and reached the highest level at 60, 30 and 5 min, respectively (Fig. 7B) . It was reported that 14-3-3 proteins were phosphoserine/phosphothreonine binding proteins, and dimeric 14-3-3 proteins could bind the FoxO1 phosphorylated by kinase ERK1/2 and Akt to form a FoxO1/14-3-3 complex, which was retained in Fig. 4 . Effect of melatonin on PC12 cell proliferation. PC12 cells were seeded in 96-well plates at a density of 4000 cells per well. Once attached, the cells were grown in serum-free medium, starved for 12 h, treated with melatonin from 0 to 2 mM for 72 h, and 10 lL of MTT (5 mgÁmL À1 in PBS) was added to each well.
Absorbance was measured at 490 nm. The differences were deemed statistically significant at P < 0.05 by Student's t test; *P < 0.05, **P < 0.01.
the cytoplasm to prevent the nuclear translocation and function of FoxO1 [62] [63] [64] . When 14-3-3 protein was phosphorylated by JNK kinase, the FoxO1-14-3-3 complex was disassembled to trigger nuclear FoxO1 translocation to initiate its transcriptional activity [65, 66] . In this study, we investigated the correlation between the phosphorylation of FoxO1, 14-3-3 protein and the up-regulated expression IDO1 by melatonin in PC12 cells. We found that the phosphorylation of FoxO1 was remarkably decreased and the phosphorylation of 14-3-3 protein was increased after the melatonin treatment (1 mM, 6 h) (Fig. 7C) . These results indicated that under these conditions, the FoxO1-14-3-3 complex was disassembled because 14-3-3 protein was phosphorylated and FoxO1 was released to be available for its transcriptional functions. Our results are similar to previous reports that 14-3-3 phosphorylation by JNK could antagonize FoxO phosphorylation by ERK1/2 and Akt to cause the release of FoxO transcription factors [62, 67, 68] . To confirm this assumption, cytoplasmic and nuclear lysates were extracted from the melatonin-treated cells, and subjected to western blot analysis (Fig. 7D,E) . As expected, FoxO1 translocated from the cytoplasm to the nucleus in a dose-dependent manner, providing another solid piece of evidence for a correlation between the transcription activity of FoxO1 and the melatonin-induced IDO1 up-regulation.
Involvement of JAK2-STAT1 and NF-jB signaling pathways in melatonin-induced IDO1 upregulation
Previous studies reported that JAK-STAT and noncanonical NF-jB signaling pathways were involved in the regulation of IDO1 expression [31, 35, 36, 69] . In this (E) Western blot of the whole protein lysates that were isolated from melatonin-treated stable IDO1 knockdown cell lines. The differences were deemed statistically significant at P < 0.05 by Student's t test; *P < 0.05, **P < 0.01. study, we examined whether the phosphorylation of JAK2, STAT1 and NF-jB was affected in the PC12 cells treated with melatonin. As shown in Fig. 8A , upon 1 mM melatonin treatment, the phosphorylation of JAK2 and STAT1 was increased in a time-dependent manner and reached the highest levels in 60 and 15 min, respectively. When the cells were pretreated with JAK2 inhibitor AG490 (10 lM) for 1 h prior to the treatment of 1 mM melatonin for 1 h, the melatonin-induced phosphorylation of JAK2 and STAT1 was blocked by AG490, and the IDO1 expression was suppressed (Fig. 8B ). In addition, we found that melatonin treatment for 15 min caused the nuclear translocation of STAT1 (Fig. 8C) . These results indicated that melatonin affected the expression of IDO1 through the JAK2-STAT1 signaling pathway in PC12 cells. As for NF-jB, we found that its expression was remarkably decreased in the stable IDO1 knockdown cells (Fig. 8D) , and upon melatonin treatment NF-jB was relocated to the nucleus (Fig. 8E) . Taken together, our results confirmed that both JAK2-STAT1 and non-canonical NF-jB signaling pathways were involved in melatonin-induced IDO1 up-regulation in PC12 cells.
Discussion
Tryptophan is an essential amino acid and an initial substrate for the biosynthesis of kynurenines, serotonin and melatonin. There are numerous reports that tryptophan metabolism influences a wide range of physiological and pathological processes, including After the cells were pretreated with 1 mM melatonin for 2 h, the nuclear extracts were isolated and then incubated with the biotin-labeled IDO1 promoter DNA, or the unlabeled IDO1 promoter DNA was added as a competitor. FoxO1 protein and IDO1 DNA complex was recognized by horseradish peroxidase-streptavidin, and visualized with a chemilluminescence imaging system. The differences were deemed statistically significant at P < 0.05 by Student's t test; *P < 0.05.
neuropathology, immune diseases and depression [2, 70, 71] . It is estimated that 99% of dietary delivered tryptophan is metabolized along the kynurenine pathway, and the remaining 1% can be converted into serotonin and melatonin [72, 73] . Apparently, though each pathway plays a critical role in keeping healthy homeostasis, the two pathways of tryptophan metabolism are extremely unequal. Very little is known about how tryptophan metabolism is equilibrated and what toxic harm may be caused to a human body when the balance of the two pathways is disturbed. Therefore, the primary purpose of this study was to explore the balance between the kynurenine and serotonin pathways.
In the present study, we found that expression of AANAT was up-regulated in stable IDO1 knockdown cells, while overexpression of AANAT inhibited IDO1 expression. On the other hand, the transfection of IDO1 expressing plasmid pEGFP-IDO1 or the treatment with a classic IDO1 inducer, IFN-c, stimulated IDO1 overexpression, resulting in decreased expression of AANAT in PC12 cells. Our results of in vitro enzymatic assay with recombinant rat IDO1 and the cellular IDO1 activity assays, analyzed by both spectrophotometry and HPLC, confirmed that melatonin had no inhibitory effect on IDO1 activity. Moreover, the expression of IDO1 and AANAT was dose-and time-dependent on melatonin treatment. In summary, these data showed that melatonin, a final product of the serotonin pathway, enhanced the kynurenine pathway, but inhibited the serotonin pathway. The significant meaning of this finding is that we found a relationship between the kynurenine and serotonin pathways.
Here, we also reported our novel findings of a new biological role for the transcription factor FoxO1 in the regulation of IDO1 and tryptophan metabolism, and a new mechanism for melatonin-induced IDO1 up-regulation. We found that the phosphorylation of JNK, Akt and ERK1/2 was significantly increased in a time-dependent manner upon melatonin treatment. Similarly to our results, JNK was previously reported The expression ratios of nuclear to cytoplasmic FoxO1 protein were analyzed by western blot. The differences were deemed statistically significant at P < 0.05 by Student's t test; *P < 0.05, **P < 0.01.
to be markedly activated in melatonin-treated LNCaP cells [73] . It was reported that the phosphorylation enhancement of ERK1/2 and Akt was of benefit to FoxO1 phosphorylation and in forming a FoxO1-14-3-3 complex [62, 64, 65] , and the enhancement of JNK phosphorylation was of benefit to 14-3-3 phosphorylation and disassembling the FoxO1-14-3-3 complex [65, 66] . Our results showed that after melatonin treatment, FoxO1 was translocated from the cytoplasm to the nucleus and the amount of translocated FoxO1 was dependent on melanin treatment dose. In addition, our ChIP assays and EMSA results revealed that melatonin enhanced the binding of FoxO1 to the IDO1 promoter. We concluded that the JNK signaling pathway, antagonizing ERK1/2 and Akt signaling pathways, played an important role in the regulation of FoxO1-mediated IDO1 expression.
It was also previously reported that IDO1 could be induced by the activation of JAK-STAT and noncanonical NF-jB signaling pathways [31, 34, 36] . Therefore, we examined whether melatonin had an effect on the above two pathways to induce IDO1 expression. Our results showed that the phosphorylation of JAK2 and STAT1 was increased by melatonin in a timedependent manner, and the increased phosphorylation was reversed by a phosphorylation inhibitor, AG490. Moreover, we discovered that melatonin also caused the nuclear translocation of STAT1 and NF-jB. Taken together, our results supported the notion that both JAK2-STAT1 and non-canonical NF-jB signaling pathways were involved in melatonin-induced IDO1 up-regulation. A proposed model to illustrate the regulation mechanism of melatonin on IDO1 expression is shown in Fig. 9 . In the lower part are nuclear to cytoplasmic expression ratios of NF-jB analyzed by western blot. The differences were deemed statistically significant at P < 0.05 by Student's t test; *P < 0.05.
In conclusion, the present study gives a better understanding of the effects of melatonin on tryptophan metabolism, and suggests the link of melatonin-JNK-FoxO1-IDO1 to be a novel regulation mechanism sustaining the balance between the kynurenine and serotonin pathways. EDTA-free cocktail inhibitor tablets and glycine, together with the other regents, were obtained from Roche (South San Francisco, CA, USA). All chemicals were of analytical grade. Antibodies were obtained from the following sources: polyclonal rabbit anti-pFoxO1 (Ser256), polyclonal rabbit anti-pJAK2 (Tyr1007/Tyr1008), polyclonal rabbit anti-pSTAT1 (Ser727), polyclonal rabbit anti-pERK1/2 (Thr202/Tyr204), polyclonal rabbit anti-pJNK (Thr183/ Tyr185), polyclonal rabbit anti-pAkt (Ser473), and polyclonal rabbit phospho-(Ser) 14-3-3 binding motif antibody from Cell Signaling Technology (Danvers, MA, USA); polyclonal mouse anti-IDO1 and polyclonal goat anti-AANAT, polyclonal rabbit anti-FoxO1, polyclonal rabbit anti-JAK2, polyclonal rabbit anti-NF-jB (non-canonical), polyclonal rabbit anti-STAT1, polyclonal rabbit anti-JNK, polyclonal rabbit anti-ERK1/2 and polyclonal rabbit antiAkt from Abcam (Cambridge, MA, USA); monoclonal anti-GAPDH antibody and anti-Lamin B1 antibody from Beyotime, China; horseradish peroxidase-conjugated secondary antibody goat anti-mouse, goat anti-rabbit and donkey anti-goat from Sigma-Aldrich.
Materials and methods
Reagents and antibodies
Cell culture
Rat adrenal pheochromocytoma (PC12) cell line was obtained from the Chinese Academy of Sciences Institute of Cell Resource Center (Shanghai, China). The PC12 cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal bovine serum (HyClone, Logan, UT, USA) and 2 mM L-glutamine, penicillin (100 UÁmL À1 ) and streptomycin (100 lgÁmL À1 ) (Invitrogen) at 37°C with 5% CO 2 and 95% humidity.
Cell viability assay
Cell viability was assessed using the MTT assay [74] . Melatonin (dissolved in DMSO) was added to the PC12 cells at the concentrations indicated in the figures. PC12 cells were seeded in 96-well plates at a density of 4000 cells per well and grown in serum-free medium, starved for 12 h prior to the addition of melatonin, then incubated for 72 h before adding 10 lL of MTT (5 mgÁmL À1 in PBS) to the culture.
After 4 h of incubation at 37°C, the supernatant of the culture was removed and replaced with 200 lL of DMSO. After the MTT formazan was completely dissolved, the absorbance was measured using an automated microplate reader at 490 nm (Thermo Fisher Scientific).
RNA extraction and first-strand cDNA synthesis
Total RNA of the PC12 cells was prepared using the Trizol reagent (Takara, Otsu, Japan) according to the manufacturer's instructions. The amount of total RNA was determined with a spectrophotometric plate reader, and the RNA integrity was assessed by agarose gel electrophoresis. In order to obtain the full-length cDNA of IDO1, TPH1, AANAT and FoxO1 genes, 2 lg of PC12 total RNA was reversetranscribed to first-strand cDNA with oligo-dT primers using the PrimeScript TM 1st Strand cDNA Synthesis Kit (Takara). The primers used for amplification are shown in Table S1 .
Construction of expression vectors and stable IDO1 knockdown PC12 cell line
For RNAi construct preparation, the full length of the IDO1 cDNA was analyzed by siDirect web (http://sidirect2. rnai.jp/) to design three different shRNA targeting IDO1 and scramble shRNA. The interference sequence was then cut with SacI and KpnI and inserted into the digested piGENE plasmid. In order to obtain stable IDO1 knockdown cell lines, PC12 cells were transfected with the piGENE plasmid containing the above shRNAs for the IDO1 gene, and after 1 lg persistent puromycin selection, three stable cell lines, rIDO1-shRNA1, rIDO1-shRNA2 and rIDO1-shRNA3, were established.
To overexpress the genes IDO1, AANAT, TPH1 and FoxO1, the expression vectors pVitro2-IDO1, pVitro2-AANAT, pVitro2-TPH1, pVitro2-AANT-TPH1 and pEGFP-FoxO1 were constructed, respectively. All the constructs were fully verified by sequencing. All the primers are listed in Table S1 .
Reverse transcription PCR (RT-PCR) and quantitative real-time PCR (qPCR)
Total RNA was isolated from PC12 cells using Trizol reagent (Takara), according to the manufacturer's protocol, and reverse-transcribed to synthesize cDNA using Premium One-Step RT-PCR kit (Invitrogen), according to the manufacturer's protocol. The target genes of IDO1, IDO2, AFMID, KMO, KYNU, 3HHAO, TPH1, TPH2, AANAT, HIOMT, IRF-1, SOCS-1, Bin1, Tyrobp, FoxO1, NF-jB, STAT1 and GAPDH were amplified by PCR with specific primers (Table S1 ). RT-PCR amplifications were carried out under the following conditions: denaturation at 95°C for 1 min, annealing at 54-60°C for 1 min (depending on the primers), and elongation at 72°C for 1 min. The number of PCR amplification cycles was 22 in this study. The PCR products were electrophoresed on 1% agarose gel. qPCR was performed in triplicate using the SYBR Green PCR Master Mix kit (Takara), with GAPDH as an internal control. The amplification program consisted of activation at 95°C for 3 min, followed by 40 amplification cycles, each consisting of 95°C for 15 s, 60°C for 15 s and elongation at 72°C for 15 s. The primers used for the quantification are shown in Table S1 . Data were analyzed using MY IQ software (Bio-Rad, California, USA).
siRNA preparation and transfection
One set of siRNA targeted for Foxo1 (sense: GCAGA CACCUUGCUAUUCATT, antisense: UGAAUAGCAA GGUGUCUGCTT) and a negative control siRNA (sense: UUCUCCGAACGUGUCACGUTT, antisense: ACGU GACACGUUCGGAGAATT) that had no homology with the rat genome were synthesized by Sangon Biotech (Shanghai, China). PC12 cells were plated in six-well plates and transfected at 70% confluence with the synthetic siRNAs using Lipofectamine TM 2000 (Invitrogen) according to the manufacturer's instructions. At 6 h after transfection, the Opti-MEMI Reduced Serum Medium (Invitrogen) was removed and the PC12 cells were supplemented with culture medium with 10% fetal bovine serum.
Recombinant rat IDO1 (rrIDO1) preparation and inhibition assay
The coding sequence of IDO1 was amplified with PCR and inserted into SalI and NotI digested pGEX-4T-1 plasmid to produce an expression vector, pGEX-rIDO1. Recombinant GST-rIDO1 fusion protein (rrIDO1) was expressed in Escherichia coli BL21(DE3)pLysS strains harboring pGEXrIDO1 plasmid after induced by 0.1 mM isopropyl b-D-1-thiogalactopyranoside, and purified by using GST-Sefinose TM Resin (Sangon Biotch) according to the manufacturer's instructions.
The effects of test compounds on rrIDO1 activity were determined as described previously with a minor modification [75, 76] . Briefly, a standard reaction mixture (0.5 mL), containing 100 mM potassium phosphate buffer (pH 6.5), 40 mM ascorbic acid (neutralized with NaOH), 200 lgÁmL À1 catalase, 20 lM methylene blue and 0.05 lM rrIDO1, was added to a solution containing a substrate L-tryptophan and a test compound at a determined concentration. The reaction was carried out at 37°C for 30 min, followed by the addition of trichloroacetic acid (TCA; 10% final concentration) and then heated at 65°C for 15 min. Subsequently, the reaction mixtures were centrifuged at 10 000 g for 5 min. The supernatant (100 lL) was transferred into a well of a 96-well microplate and mixed with isometric 2% (w/v) p-dimethylaminobenzaldehyde in acetic acid. The absorbance was measured at 490 nm on a spectrophotometric plate reader (Thermo Fisher Scientific).
For the cellular IDO1 inhibition activity assay, PC12 cells were seeded in a 96-well culture plate at a density of 2.5 9 10 4 cells per well and cultured for 24 h, then supplemented with substrate L-Trp and a serial dilution of the tested compounds in 200 lL culture medium. After an additional 24 h incubation, 140 lL of the supernatant per well was transferred to a new 96-well plate and mixed with 10 lL of 30% TCA in each well. The plate was incubated at 56°C for 15 min to hydrolyze N-formylkynurenine produced by the catalytic reaction of IDO1. The reaction mixture was then centrifuged for 10 min at 10 000 g to remove the sediment. Then, 100 lL of the supernatant per well was transferred to another new 96-well plate and mixed with 100 lL of 2% (w/v) p-dimethylaminobenzaldehyde in acetic acid. The yellow color derived from kynurenine was measured at 490 nm using a SPECTRAmax 250 microplate reader.
HPLC assay
The enzymatic activities of IDO and AANAT were evaluated by measuring the levels of tryptophan and kynurenine [54, 77, 78] and melatonin [79] by HPLC as previously reported. The culture medium from PC12 cells was treated with 30% TCA to remove protein and the supernatants were subjected to HPLC analysis. The analysis was performed on an Agilent 1260 series HPLC system (Agilent Technologies, Santa Clara, CA, USA) equipped with a quat pump and a UV detector.
Western blot
To find the effects of various test samples (IFN-c, 1-L/D-MT or melatonin) on the expression of some proteins of interest, western blot analyses were performed. PC12 cells were seeded in six-well plates, allowed to attach, and then incubated with the test samples at the indicated concentrations for 48 h. In phosphorylation inhibition experiments, the PC12 cells were pretreated for 1 h with phosphotransferase inhibitors, such as 10 lM SP600125 (JNK inhibitor), 10 lM LY294002 (Akt inhibitor), 25 lM PD98059 (ERK1/2 inhibitor) or 10 lM AG490 (JAK2 inhibitor) prior to supplementation of melatonin at the indicated concentrations. Cells were triple washed with ice-cold PBS, lysed by adding 500 lL of ice-cold radioimmunoprecipitation assay lysis buffer (50 mM Tris/HCl, pH 7.4, 0.1% SDS, 1% nonidet P-40, 0.5% deoxycholate, 150 mM NaCl, 5 mM EDTA, protease cocktail inhibitor and 1 mM phenylmethylsulfonyl fluoride) for 30 min at 4°C, and then scraped off the plates. After centrifugation for 10 min at 10 000 g at 4°C, the supernatant was collected as a total lysate. Protein concentration was determined using the Pierce BCA Protein Assay Kit (Pierce/Thermo Fisher Scientific). Equal amounts of the protein (20 lg) were separately subjected to SDS/ PAGE and transferred to a polyvinylidene fluoride membrane (Millipore, Billerica, MA, USA). Membranes were blocked with 5% nonfat dried milk in PBS supplied with 0.1% tween 20 for 1 h at room temperature, and then incubated with various corresponding primary antibodies. The expression of IDO1, AANAT, FoxO1, pFoxO1, STAT1, pSTAT1, NF-jB, JNK, pJNK, Akt, pAkt, ERK1/2, pERK1/2, JAK2, pJAK2, p14-3-3, Lamin B1 and GAPDH was detected by anti-IDO1 antibody (1: 1000 dilution), anti-AANAT antibody (1 : 500 dilution), anti-FoxO1 antibody (1 : 1000 dilution), anti-pFoxO1 antibody (1 : 500 dilution), anti-STAT1 antibody (1 : 1000 dilution), antipSTAT1 antibody (1 : 500 dilution), anti-NF-jB antibody (1 : 1000 dilution), anti-JNK antibody (1 : 1000 dilution), anti-pJNK antibody (1 : 500 dilution), anti-Akt antibody (1 : 1000 dilution), anti-pAkt antibody (1 : 500 dilution), anti-ERK1/2 antibody (1 : 1000 dilution), anti-pERK1/2 antibody (1 : 500 dilution), anti-JAK2 antibody (1 : 1000 dilution), anti-pJAK2 antibody (1 : 500 dilution), anti-p14-3-3 antibody (1 : 500 dilution), anti-Lamin B1 antibody (1 : 1000 dilution) and anti-GAPDH antibody (1 : 2000 dilution), respectively. Following overnight incubation, the membranes were washed and incubated for 1 h in horseradish peroxidase (HRP)-conjugated secondary antibodies. HRP-conjugated secondary antibodies were detected by chemilluminescence with enhanced chemiluminescence (GE Healthcare, Chicago, IL, USA).
Chromatin immunoprecipitation assay
To determine the effect of melatonin on the cross-linking of FoxO1 protein and IDO1 promoter, ChIP assays were performed using a Pierce Agarose ChIP Kit (Thermo Fisher Scientific) according to the manufacturer's instructions with slight modifications. PC12 cells were pretreated with melatonin for 2 h, then subjected to formaldehyde (final concentration of 1%) and incubated for 10 min at room temperature. After the addition of glycine (final concentration of 125 mM), the cells were sonicated and immunoprecipitated as described previously [80, 81] . The DNA-protein complexes were immunoprecipitated with anti-FoxO1 (Cell Signaling Technology, Danvers, MA, USA). Precipitated DNA fragments were amplified by qPCR, which was performed using primers specific for the IDO1 promoter: forward primer, 5 0 -TTTCACGAGAACA GGTAATGGCTC-3 0 and reverse primer, 5 0 -GGAGGG TTGTCCACCTTTTCTACTAT-3 0 .
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Electrophoresis mobility shift assay
Nuclear extracts were prepared from PC12 cells after treated with 1 mM melatonin for 2 h, according to the method previously described [82] and an electrophoretic mobility shift assay (EMSA) was conducted using LightShift Ò Chemiluminescent EMSA Kit (Thermo Fisher Scientific) according to the manufacturer's protocols [83, 84] . Briefly, the binding reaction mixture, containing nuclear extract, binding buffer, biotin-labeled probe or a certain amount of unlabeled-probe as the competitor was incubated at room temperature for 10 min prior to running on a 5% polyacrylamide gel, recognized by HRP-streptavidin, and visualized with a chemilluminescence imaging system (GE Healthcare). The probe primers are listed in Table S1 .
Luciferase reporter assay
To generate luciferase reporters, the full length of IDO1 promoter was PCR-amplified from the genomic DNA extracted from PC12 cells using specific primers as follows: forward primer, 5 0 -CGGGGTACCGTTTACAAAAGCT GATTGCT-3 0 and reverse primer, 5 0 -CCCAAGCTTC TGTCTTTCCCACTGGACTC-3 0 , and subcloned into the pGL3-basic vector via KpnI and HindIII sites yielding the pGL3-IDO1 vector. PC12 cells were cultured to 70-80% confluence to be transfected with 200 ng pGL3-IDO1 plasmid and 20 ng pRL-TK plasmid (Promega, Madison, WI, USA) using Lipofectamine TM 2000 (Invitrogen) as recommended by the manufacturer. The purpose of the co-transfection of pRL-TK was to normalize the transfection efficiency. At 24 h post-transfection, the cells were analyzed using a luciferase assay kit (Promega) according to the manufacturer's instructions.
Statistics
All photo-images of semi-quantitative RT-PCR and western blot were representative of at least three independent experiments. Quantitative RT-PCR was performed in triplicate and each experiment was repeated several times. Data shown were represented as the mean AE standard error of the mean (SEM) of three or more independent experiments, and the differences were deemed statistically significant at P < 0.05 by Student's t-test. 
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